Page last updated: 2024-12-06
9-oxononanoic acid
Description
9-oxononanoic acid, also known as pelargonic acid, is a nine-carbon fatty acid with a ketone functional group at the 9-position. It is a colorless liquid with a pungent odor, and it is found in nature in some plants and animals. 9-oxononanoic acid is a potent inducer of the peroxisome proliferator-activated receptor alpha (PPARα), a nuclear receptor that plays an important role in lipid metabolism. Activation of PPARα by 9-oxononanoic acid leads to increased expression of genes involved in fatty acid oxidation, reducing serum triglycerides and cholesterol levels. It has been studied as a potential therapeutic agent for the treatment of dyslipidemia, hyperlipidemia, and cardiovascular diseases. However, further research is needed to fully understand its safety and efficacy in humans. The compound has also been studied for its potential to stimulate the production of insulin, suggesting potential applications in the treatment of diabetes.'
9-oxononanoic acid: effects lipogenesis in rat liver [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
9-oxononanoic acid : A medium-chain oxo-fatty acid that is the 9-oxo derivative of nonanoic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 75704 |
| CHEBI ID | 78700 |
| SCHEMBL ID | 1603841 |
| MeSH ID | M0154901 |
Synonyms (28)
| Synonym |
|---|
| 9-ketononanoic acid |
| 2553-17-5 |
| 9-oxononanoic acid |
| 9-oxo-nonanoic acid |
| LMFA01060160 |
| AKOS006239261 |
| nonanoic acid, 9-oxo- |
| unii-yh3q8rsx3z |
| yh3q8rsx3z , |
| SCHEMBL1603841 |
| 8-formyloctanoic acid |
| CHEBI:78700 |
| WLGDDELKYAWBBL-UHFFFAOYSA-N |
| AC-33586 |
| DTXSID30180228 |
| Q27147919 |
| mfcd05864080 |
| BS-16263 |
| nonanal-9-oic acid |
| .omega.-oxononanoic acid |
| azelaaldehydic acid |
| fa 9:1+1o |
| C74321 |
| SY253223 |
| 9-oxononanoicacid |
| EN300-220107 |
| CAA55317 |
| PD131330 |
Roles (1)
| Role | Description |
|---|
| EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor | An EC 6.4.1.* (C-C bond-forming ligase) inhibitor that interferes with the action of acetyl-CoA carboxylase (EC 6.4.1.2). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (3)
| Class | Description |
|---|
| aldehydic acid | A monocarboxylic acid derived from any dicarboxylic acid that has a retained name by the formal reduction of one of the carboxy groups to a formyl group. The resulting structure, also known as a semialdehyde, may be named by replacing the ending '...ic acid' of the retained name of the dicarboxylic acid by the ending '...aldehydic acid'. Aldehydic acids therefore contain one carboxy group and one aldehyde group. |
| omega-oxo fatty acid | Any oxo fatty acid in which the oxo group is located at the omega-position. |
| medium-chain fatty acid | Any fatty acid with a chain length of between C6 and C12. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 29.22
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 29.22 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.32 (4.65) | | Search Engine Demand Index | 28.85 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |